Insider Selling: REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $101,100.00 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

REGENXBIO Price Performance

Shares of RGNX stock opened at $9.72 on Friday. The company has a market cap of $478.77 million, a PE ratio of -1.65 and a beta of 1.21. REGENXBIO Inc. has a 1 year low of $9.29 and a 1 year high of $28.80. The stock’s 50 day simple moving average is $11.94 and its two-hundred day simple moving average is $14.21.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.24. The company had revenue of $22.30 million for the quarter, compared to analyst estimates of $22.97 million. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. REGENXBIO’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.66) EPS. Equities research analysts expect that REGENXBIO Inc. will post -4.66 EPS for the current year.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently made changes to their positions in the company. Redmile Group LLC raised its position in REGENXBIO by 21.0% in the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after purchasing an additional 790,866 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 258.7% during the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after buying an additional 588,773 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of REGENXBIO by 9.8% in the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after buying an additional 436,043 shares during the period. Perceptive Advisors LLC bought a new stake in shares of REGENXBIO during the 4th quarter worth approximately $6,146,000. Finally, Artal Group S.A. purchased a new position in REGENXBIO during the 1st quarter valued at $5,268,000. Institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on RGNX shares. Barclays lowered their price objective on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. The Goldman Sachs Group initiated coverage on shares of REGENXBIO in a research note on Friday, June 7th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.91.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.